

Anti-Integrin $\alpha 4\beta 7$ (ITGA4 & ITGB7) Antibody (Etolizumab)

Introduction

Etolizumab (rhUMab Beta7) is a gut-selective anti- $\beta 7$ integrin monoclonal antibody. Etolizumab is a specific active molecule targeting the $\beta 7$ subunit of $\alpha 4\beta 7$ and $\alpha E\beta 7$ integrins. Etolizumab can be used in the research of inflammatory bowel disease (IBD).

Product parameters

Alternative Names	rhUMab Beta7, Anti-beta7, PRO145223
Target Accession	P13612 & P26010
Target	Integrin $\alpha 4\beta 7$ (ITGA4 & ITGB7)
CAS number	1044758-60-2
Molecular Weight	144.3 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

